Please assess the completion status of the following clinical trial:

Trial Title: Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cirrhotic patients, potential candidates for liver transplantation, with indication to HBV vaccination (HBsAg negative and anti-HBs negative).~2. Patients under treatment with HBVAXPRO® who do not show a response after the first cycle of vaccination of three intramuscular doses of 40 µg at 0, 1 and 2 months.~3. Patients over 18 years old.~4. Negative pregnancy test.~5. Patients who have given their consent to participate in the study.~Exclusion Criteria:~1. Absolute contraindication to HBV vaccine.~2. Medical history of allergy to any component of the vaccine.~3. Chronic renal failure on hemodialysis.~4. Presence of antibodies against Human Immunodeficiency Virus.~5. Patients with seroconversion (anti-HBs \> 10 IU /ml) after the first three doses of vaccine.~6. Lack of consent to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Second HBV vaccination cycle (Type: EXPERIMENTAL): Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
- Single dose of HBV vaccine (Type: ACTIVE_COMPARATOR): Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).